Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma

被引：6

作者：

Godfrey, James K. ^{[1
]}

Gao, Lei ^{[1
]}

Shouse, Geoffrey ^{[1
]}

Song, Joo Y. ^{[2
]}

Pak, Stacy ^{[3
]}

Lee, Brian

Chen, Bihong T. ^{[4
]}

Kallam, Avyakta ^{[1
]}

Baird, John H. ^{[1
]}

Marcucci, Guido ^{[1
]}

Ghoda, Lucy ^{[5
]}

Vauleon, Stephanie ^{[6
]}

Danilov, Alexey V. ^{[1
]}

Herrera, Alex F. ^{[1
]}

Kwak, Larry W. ^{[1
]}

Budde, Lihua E. ^{[1
]}

机构：

[1] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA USA

[2] City Hope Natl Med Ctr, Dept Pathol, Duarte, CA USA

[3] City Hope Natl Med Ctr, Dept Pharm, Duarte, CA USA

[4] City Hope Natl Med Ctr, Dept Diagnost Radiol, Duarte, CA USA

[5] Beckman Res Inst City Hope, Dept Hematol Malignancies & Translat Sci, Duarte, CA USA

[6] F Hoffmann La Roche Ltd, Roche Innovat Ctr Basel, Roche Pharm Res & Early Dev, Pharmaceut Sci, Basel, Switzerland

来源：

BLOOD | 2024年 / 144卷 / 04期

基金：

美国国家卫生研究院;

关键词：

PHASE-I; RITUXIMAB; THERAPY; TRANSPLANTATION; INVOLVEMENT;

D O I：

10.1182/blood.2024024168

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Although CD20×CD3 bispecific antibodies are effective against systemic B-cell lymphomas, their efficacy in central nervous system (CNS) lymphoma is unknown. Here, we report the CD20×CD3 bispecific glofitamab penetrates the blood-brain barrier, stimulates immune-cell infiltration of CNS tumors, and induces clinical responses in patients with secondary CNS. © 2024 American Society of Hematology

引用

页码：457 / 461

页数：5